Fosun Pharmaceuticals grabbed Azfdin, does the new Guan special medicine need commercialization?

On the evening of July 25, the State Drug Administration disclosed the announcement: Azu, Azf, to increase the indication of Azf fixed chip of Henan True Biotechnology Co., Ltd.

This explosive news immediately swipes the screen,

On the evening of July 25, the State Drug Administration disclosed the announcement: Azifan Azf Fixed Pineries of Henan Real Biotechnology Co., Ltd. increased the indications for the treatment of adult patients in ordinary new crown pneumonia.

This explosive news immediately swipes the screen. Azf was designated as the first domestic new crown oral medication, throwing the VV116 of the Junshi creature and the Pukluamide of the pioneering pharmaceutical industry behind him.

That night, Fosun Pharmaceutical issued an announcement saying that it reached a strategic cooperation with real creatures. The two sides jointly developed Azfdin, and Fosun Pharmaceutical obtained the exclusive commercial authority of Azf in the field of new crown virus, AIDS therapy and prevention.

Before obtaining the new crown indications, the value of Azfding's industrial chain was almost finished by several listed companies such as China Resources Shuanghe and Aoxiang Pharmaceutical. Now Fosun Pharmaceuticals emerge, causing the market to be caught off guard.

There is a voice that Azf will "marry more daughters."

The Jianzhi Bureau was informed that Azf's current supply capacity is 200 million people per year. It seems that as long as it can be sold, it will definitely make a lot of money. However, the news was announced the next day. On July 26, the "Azf Concept Stock" fell almost across the board. Ao Xiang Pharmaceutical fell 10%, China Resources Shuanghe fell 10.01%, Tuoxin Pharmaceuticals fell 6.27%, Xinhua Pharmaceutical rose slightly by 0.63%, and even Fosun Pharmaceutical fell 3.11%.

From the perspective of the new crown special drug revenue share, the current epidemic prevention and control, and the market attitude, the "new crown concept" is no longer new, and the new crown special medicine is no longer special.

Fosun "Tiehu"

The cooperation between Fosun Pharmaceutical and real creatures is divided into two regions. Regional 1 is China in China that does not include Hong Kong, Macao and Taiwan. Regional 2 is the global region other than regional 1, but does not include Russia, Ukraine, Brazil, and other South American countries and other South American countries and other South American countries and other South American countries and other South American countries and other South American countries and other South American countries and other South American countries and other South American countries and other South American countries and other South American countries and other South American countries and other South American countries and other South American countries and other South American countries area.

The two regions basically include the global market. According to the cooperation agreement, Fosun Pharmaceutical gives a total of nearly 800 million "sincerity" to real creatures, of which 500 million yuan will be paid quickly:

//

Within 5 working days after signing the agreement, Fosun Pharmaceutical paid 100 million yuan to real biological biology;

For the domestic market cooperation, after completing the diligence and evaluation of real creatures, Fuxing Pharmaceutical should pay 399.5 million yuan to the latter;

In response to the cooperation of foreign markets, Fosun Pharmaceutical should pay 300 million yuan to real biological biology after diligence and evaluation.

In terms of interest division, Fosun Pharmaceutical is very generous: the commercial costs in the relevant areas are borne by themselves, and the two gross profit generated by the Chinese market will be divided into two. Foreign sharing is to be determined.

Such a great sincerity may be to take the "exclusive" commercial rights. Real creatures have promised many companies, and Azf would not know how many times "sold".

As early as in late April, the news of "real creature Azfding is about to be approved" has spread on the market, and many companies have begun to announce that they are in touch with Azf:

On April 26, Shandong Xinhua Pharmaceutical stated that it had signed a strategic cooperation agreement with real creatures to become a product and dealer in China such as Azfding and other countries.

On May 6, Tuoxin Pharmaceutical announced that the new production line of its Azf Fixed Materials Pharmaceutical passed the GMP compliance inspection, which can expand the production capacity into production;

On May 8th, China Resources Shuanghe issued an announcement to get the Azf's fixed film entrusted processing production framework agreement;

On May 10, Ao Xiang Pharmaceutical issued an announcement that his wholly -owned subsidiary Zhejiang Qizheng Pharmaceutical and real creature signed the "Entrusted Processing Production Framework Agreement" and "Drug Administrative Quality Agreement" ...

Fosun Pharmaceutical and Real Biological Signida are "exclusive" agreements. In terms of effectiveness, it seems to be higher than the above. Of course, the cost of flowers is even greater. Fosun got an early early crown MRNA vaccine and failed to get much returns. Now he vowed to recover one game on the new crown special medicine?

His business value

The problem in front of Azf is: New crown indications, do you need commercialization?

There are currently two types of new crown special drugs that have been listed in China. One is Paxlovid of Pfizer, and the other is the Ambaleko monoclonal anti -anti -antidote combination therapy of Teng Shengbo medicine. The former is oral medication, and the latter is neutralized antibody injection. The main business models of these two medicines at home and abroad are centralized government procurement.

Regarding commercial operation, Luo Yongqing, president of Teng Shengbo Pharmaceutical and General Manager of Greater China, said: This medicine is different from traditional drugs. "Its main marketing model is government procurement, so the company's commercialized team will not be too large."

At present, Teng Shengbo's Anbawei's monoclonal anti -anti -anti -anti -anti -anti -anti -anti -injection injection in the United States is in the stage of applying for an emergency use authorization (EUA) to FDA, and has not yet been listed. According to its estimates, the government procurement share of neutralized antibody drugs in the US market is only millions of people, and the government procurement price per person is $ 1500-2,000.

The sales method of the new crowd special medicine must be based on government management and control, and it cannot be marketing as many channels as traditional medicines. How much medicine can be sold is how much the government needs. How much the government needs is closely related to the prevention and control of the new crown epidemic in various countries.

Pfizer has used PaxLovid's revenue performance to break the potting of global investors: According to the previous telephone meeting, Pfizer disclosed that in the first quarter of 2022, PaxLovid's global revenue was 1.47 billion US dollars, far lower than the market expectations of US $ 2.42 billion.It is not a star difference between the target of achieving a revenue of 22 billion yuan throughout the year.Azf's new crown indications in the country is commercialized in China. The sales profit cannot be too large. The most realistic is the part of logistics and distribution, and the profit is also very low.

Fosun Pharmaceuticals may expect the commercial rights and interests of overseas markets.According to reports, Fosun Pharmaceuticals will contract Azf's approval and sales overseas.Especially in African countries, Fosun's channels have certain advantages.

Regarding Azfdin's toxic and side effects, some relevant persons told Jianzhi Bureau: "Azfdin itself is AIDS medication approved for listing. For long -term use, safety must be guaranteed.disease."

#### 医 药 药 ## Real creature#

- END -